المؤلفون: Mohammed M. Milhem, Peter Mohr, Paul Nathan, Piotr Rutkowski, Anthony D'Amelio, Peter Hersey, Felix Kiecker, Jochen Utikal, Lev V. Demidov, Caroline Robert, Reinhard Dummer, Claus Garbe, Dirk Schadendorf, Jessica C. Hassel, Bijoyesh Mookerjee, James Larkin, Keith T. Flaherty

المساهمون: Department of Dermatology (CHU Besançon), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), N.N. Blokhin Russian Cancer Research Center, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Novartis Pharmaceutical Corporation, University of Zurich, Robert, Caroline

المصدر: European Journal of Cancer
European Journal of Cancer, Elsevier, 2019, 109, pp.61-69. ⟨10.1016/j.ejca.2018.12.015⟩

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, Time Factors, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Medizin, Phases of clinical research, Targeted therapy, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, 1306 Cancer Research, Melanoma, Trametinib, Aged, 80 and over, Brain Neoplasms, MEK inhibitor, Hazard ratio, 10177 Dermatology Clinic, Middle Aged, Prognosis, 3. Good health, Dacarbazine, Survival Rate, 030220 oncology & carcinogenesis, 2730 Oncology, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Paclitaxel, Pyridones, 610 Medicine & health, Pyrimidinones, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, Adverse effect, Aged, Chemotherapy, business.industry, 030104 developmental biology, Mutation, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28197cc98bbc5b4b985accfda8ddbdbdTest
https://pubmed.ncbi.nlm.nih.gov/30690294Test

المؤلفون: John M. Kirkwood, James Larkin, Mario Mandalà, Richard F. Kefford, Tomas Haas, Vanna Chiarion-Sileni, Caroline Robert, Kohinoor Dasgupta, Axel Hauschild, Mario Santinami, Mark Shilkrut, Caroline Dutriaux, Eduard Gasal, Dirk Schadendorf, Georgina V. Long, Jacob Schachter, Andrew Haydon, Laurent Mortier, Ruth Plummer, Victoria Atkinson, Marta Nyakas, Thierry Lesimple, Reinhard Dummer

المساهمون: University of Zurich, Long, Georgina V

المصدر: Journal of Clinical Oncology
J Clin Oncol

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, Internationality, Skin Neoplasms, Time Factors, Medizin, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, Clinical endpoint, 1306 Cancer Research, Stage (cooking), Melanoma, Trametinib, Hazard ratio, Age Factors, Imidazoles, 10177 Dermatology Clinic, Middle Aged, Treatment Outcome, 030220 oncology & carcinogenesis, Female, 2730 Oncology, Rapid Communication, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, 610 Medicine & health, Pyrimidinones, Placebo, Disease-Free Survival, Drug Administration Schedule, 03 medical and health sciences, Sex Factors, Adjuvants, Immunologic, Double-Blind Method, Internal medicine, Correspondence, medicine, Humans, Dose-Response Relationship, Drug, business.industry, Cancer, Dabrafenib, medicine.disease, Clinical trial, 030104 developmental biology, business, Follow-Up Studies

وصف الملف: 767_Hauschild_A._et_al._Longer_follow-up_confirms_relapse-free_survival_benefit_with_adjuvant_dabrafenib_plus_trametinib_in_patients_JCO_2018.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00393631f41ac7c8491c0de2c7f007a8Test
https://doi.org/10.5167/uzh-158265Test

المؤلفون: Christian U. Blank, Adil Daud, Rene Gonzalez, Kim Margolin, Scot Ebbinghaus, Ziwen Wei, Dirk Schadendorf, Antoni Ribas, Anna C. Pavlick, Lee D. Cranmer, Caroline Robert, April K.S. Salama, Jacob Schachter, Omid Hamid, Reinhard Dummer, Nageatte Ibrahim, F. Stephen Hodi, Igor Puzanov, Tara C. Gangadhar, Paolo A. Ascierto

المساهمون: University of Zurich, Hamid, Omid

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, Time Factors, medicine.medical_treatment, Medizin, Phases of clinical research, Pembrolizumab, Kaplan-Meier Estimate, 0302 clinical medicine, Antineoplastic Agents, Immunological, 1306 Cancer Research, Melanoma, Aged, 80 and over, education.field_of_study, Cross-Over Studies, Drug Substitution, Hazard ratio, 10177 Dermatology Clinic, Middle Aged, MAP Kinase Kinase Kinases, Treatment Outcome, 030220 oncology & carcinogenesis, Disease Progression, 2730 Oncology, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Adolescent, Population, Ipilimumab, 610 Medicine & health, Antibodies, Monoclonal, Humanized, Disease-Free Survival, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Humans, education, Protein Kinase Inhibitors, Aged, Chemotherapy, business.industry, medicine.disease, Confidence interval, Surgery, 030104 developmental biology, Drug Resistance, Neoplasm, Mutation, business

وصف الملف: 721_Hamid_O._et_al._Final_analysis_of_randomised_trial_comparing_pembrolizumab_versus_Eur_J_Cancer_2017.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab24a3779538f584d0432f320113cbb5Test
https://www.ncbi.nlm.nih.gov/pubmed/28961465Test

المؤلفون: Céleste Lebbé, Anna Maria Di Giacomo, Helen Gogas, Georgina V. Long, Paolo A. Ascierto, Catalin Mihalcioiu, Francesco Cognetti, Ewa Kalinka-Warzocha, Kerry J. Savage, Cornelia Mauch, Ana Arance, Jasmine I. Rizzo, Lars Ny, Caroline Dutriaux, Piotr Rutkowski, Caroline Robert, Micaela Hernberg, Victoria Atkinson, Vanna Chiarion-Sileni, Benjamin Brady, Inge Marie Svane, Dirk Schadendorf, Jessica C. Hassel, Julie Charles, Laurent Mortier, Catriona M. McNeil, Abdel Saci, Joel Jiang

المصدر: JAMA Oncol

مصطلحات موضوعية: advanced melanoma, Adult, Male, Proto-Oncogene Proteins B-raf, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Time Factors, Adolescent, Dacarbazine, Medizin, Phases of clinical research, Ipilimumab, Pembrolizumab, Placebo, BRAF, Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Double-Blind Method, Internal medicine, medicine, Humans, 030212 general & internal medicine, Nivolumab, wild-type, Antineoplastic Agents, Alkylating, Melanoma, Aged, Aged, 80 and over, business.industry, Hazard ratio, Correction, Middle Aged, medicine.disease, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Disease Progression, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3c9b0d0b1e4e0e7e07096a725b4e567Test
https://doi.org/10.1001/jamaoncol.2018.4514Test

المؤلفون: Pascal Wolter, Dirk Schadendorf, Daniil Stroiakovski, Michael Lichinitser, Jeff Legos, Paul Nathan, Peng Sun, Kamil Drucis, Keith T. Flaherty, Boguslawa Karaszewska, Antoni Ribas, Florent Grange, Anne-Marie Martin, Shonda M Little, Reinhard Dummer, Ivana Krajsová, Laurent Mortier, Vanna Chiarion-Sileni, Wendy A. Crist, Paul Lorigan, Stephen D. Rubin, Andrzej Mackiewicz, Piotr Rutkowski, Jacob Schachter, Caroline Robert, Georgina V. Long, Axel Hauschild

المساهمون: University of Zurich, Robert, Caroline

مصطلحات موضوعية: Oncology, Male, Keratoacanthoma, Indoles, Skin Neoplasms, Medizin, Kaplan-Meier Estimate, 2700 General Medicine, chemistry.chemical_compound, Antineoplastic Combined Chemotherapy Protocols, Oximes, Vemurafenib, Melanoma, Trametinib, Aged, 80 and over, education.field_of_study, Sulfonamides, Hazard ratio, Imidazoles, 10177 Dermatology Clinic, General Medicine, Middle Aged, Intention to Treat Analysis, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Adolescent, Pyridones, Population, 610 Medicine & health, Pyrimidinones, Young Adult, Internal medicine, medicine, Humans, education, neoplasms, Protein Kinase Inhibitors, Aged, Cobimetinib, Mitogen-Activated Protein Kinase Kinases, business.industry, Dabrafenib, medicine.disease, Survival Analysis, Surgery, chemistry, Mutation, business

وصف الملف: Robert C et al. - N Engl J Med 2014.pdf - application/pdf; Print-Electronic; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb174f02e29f4375b8bd8c23ddb74764Test
https://doi.org/10.5167/uzh-107163Test

المؤلفون: Daniil Stroyakovskiy, Peter Mohr, Virginia Ferraresi, Michael Millward, Paul Nathan, Claus Garbe, Filippo de Braud, Caroline Robert, Jhangir G. Irani, Igor Bondarenko, Vanna Chiarion-Sileni, Jochen Utikal, Nadezhda Kovalenko, Douglas J Demarini, Bijoyesh Mookerjee, James Larkin, Ana Arance, Suzanne Swann, Mario Mandalà, Axel Hauschild, Jeffrey J. Legos, John B. A. G. Haanen, Jean-Jacques Grob, Keith T. Flaherty, Antoni Ribas, Johan Hansson, Dirk Schadendorf, Georgina V. Long, Thomas Jouary, Helen Gogas, Fan Jin, Volodymr Probachai, Céleste Lebbé, Evgeny Levchenko

مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, Oncology, medicine.medical_specialty, Pyridones, Medizin, Phases of clinical research, Pyrimidinones, Placebo, Disease-Free Survival, Young Adult, chemistry.chemical_compound, Double-Blind Method, Internal medicine, Oximes, medicine, Clinical endpoint, Humans, Melanoma, Aged, Aged, 80 and over, Trametinib, Cobimetinib, business.industry, Hazard ratio, Imidazoles, Dabrafenib, General Medicine, Middle Aged, medicine.disease, Surgery, Treatment Outcome, chemistry, Drug Therapy, Combination, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7305a840ef7860ce6dbedc881e5fe7cfTest
http://hdl.handle.net/11391/1480871Test

المؤلفون: Victoria Atkinson, Céleste Lebbé, Jessica C. Hassel, Catalin Mihalcioiu, Cornelia Mauch, Ewa Kalinka-Warzocha, Ian M. Waxman, Ana Arance, Piotr Rutkowski, Kerry J. Savage, Vanna Chiarion-Sileni, Caroline Dutriaux, Micaela Hernberg, Abstr Act, Laurent Mortier, Catriona M. McNeil, Brian Sharkey, Caroline Robert, Dirk Schadendorf, Michele Maio, Christine Horak, Georgina V. Long, Lotta Lundgren-Eriksson, Benjamin Brady, Helen Gogas, Francesco Cognetti, Henrik Schmidt, Paolo A. Ascierto, Julie Charles

المصدر: Robert, C, Long, G V, Brady, B, Dutriaux, C, Maio, M, Mortier, L, Hassel, J C, Rutkowski, P, McNeil, C, Kalinka-Warzocha, E, Savage, K J, Hernberg, M M, Lebbé, C, Charles, J, Mihalcioiu, C, Chiarion-Sileni, V, Mauch, C, Cognetti, F, Arance, A, Schmidt, H, Schadendorf, D, Gogas, H, Lundgren-Eriksson, L, Horak, C, Sharkey, B, Waxman, I M, Atkinson, V & Ascierto, P A 2015, ' Nivolumab in previously untreated melanoma without BRAF mutation ', The New England Journal of Medicine, vol. 372, no. 4, pp. 320-30 . https://doi.org/10.1056/NEJMoa1412082Test
New England Journal of Medicine; 372(4), pp 320-330 (2015)

مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Adolescent, Dacarbazine, Programmed Cell Death 1 Receptor, Medizin, Phases of clinical research, Ipilimumab, Antineoplastic Agents, Pembrolizumab, ipilimumab-refractory metastatic melanoma, Gastroenterology, Disease-Free Survival, Young Adult, Double-Blind Method, Nivolumab, melanoma, ipilimumab-refractory metastatic melanoma, Internal medicine, Medicine, Humans, Survival rate, Melanoma, Aged, Aged, 80 and over, business.industry, Hazard ratio, Antibodies, Monoclonal, General Medicine, Middle Aged, medicine.disease, Surgery, Survival Rate, Nivolumab, Cancer and Oncology, Female, business, medicine.drug

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07253c758028e0b62a420832a391b6ecTest
https://pubmed.ncbi.nlm.nih.gov/25511188Test

المؤلفون: Daniil Stroyakovskiy, Jochen Utikal, Keith T. Flaherty, Daniele Ouellet, Virginia Ferraresi, Michelle Casey, Claus Garbe, Axel Hauschild, V. Chiarion Sileni, Caroline Robert, Helen Gogas, Antoni Ribas, Michael Millward, Nadezhda Kovalenko, Jean-Jacques Grob, Jhangir G. Irani, Paul Nathan, Dirk Schadendorf, John B. A. G. Haanen, V. Probachai, Mario Mandalà, F. de Braud, Johan Hansson, Georgina V. Long, Igor Bondarenko, Kiran Patel, Ngocdiep T. Le, Anne-Marie Martin, James Larkin, Ana Arance, T. Jouary, Peter Mohr, Douglas J. DeMarini, Céleste Lebbé, Evgeny Levchenko

مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Fever, Pyridones, Medizin, Kaplan-Meier Estimate, Pyrimidinones, Gastroenterology, Disease-Free Survival, chemistry.chemical_compound, Double-Blind Method, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Oximes, Carcinoma, medicine, Clinical endpoint, Humans, Melanoma, Aged, Mitogen-Activated Protein Kinase Kinases, Cobimetinib, Trametinib, business.industry, Hazard ratio, Imidazoles, Binimetinib, Dabrafenib, General Medicine, Middle Aged, medicine.disease, Surgery, chemistry, Mutation, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::266d13e0581ba3c486d28c2d159ca1daTest
http://hdl.handle.net/11391/1480877Test

المؤلفون: Kerstin Trunzer, Antoni Ribas, C. Lebbé, Dirk Schadendorf, Paul B. Chapman, Jeffrey A. Sosman, Axel Hauschild, Alessandro Testori, Omid Hamid, Paolo A. Ascierto, Grant A. McArthur, Michele Maio, John M. Kirkwood, Thomas Jouary, Brigitte Dréno, Alexander M.M. Eggermont, John B. A. G. Haanen, James Larkin, Claus Garbe, Reinhard Dummer, Ivor Caro, Ming Yin, Paul Lorigan, Stephen J O'Day, Suzanne Cheng, David Hogg, Keith T. Flaherty, Caroline Robert

المساهمون: University of Zurich, McArthur, Grant A

المصدر: The Lancet. Oncology, vol 15, iss 3

مصطلحات موضوعية: Male, Indoles, Medizin, Gastroenterology, chemistry.chemical_compound, Vemurafenib, Melanoma, Cancer, Sulfonamides, education.field_of_study, Hazard ratio, 10177 Dermatology Clinic, Binimetinib, Middle Aged, Dacarbazine, Oncology, 2730 Oncology, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Clinical Trials and Supportive Activities, Oncology and Carcinogenesis, Population, 610 Medicine & health, Disease-Free Survival, Clinical Research, Internal medicine, Genetics, medicine, Humans, Oncology & Carcinogenesis, education, Protein Kinase Inhibitors, Aged, Cobimetinib, Performance status, business.industry, Prevention, medicine.disease, Surgery, Good Health and Well Being, chemistry, Mutation, business, Follow-Up Studies

وصف الملف: 573_McArthur_GA_et_al._-_Lancet_Oncol_2014.pdf - application/pdf; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::377d825d8360489bb92f735b7e5e1cb4Test
http://hdl.handle.net/11365/1081256Test

المؤلفون: Keith T, Flaherty, Caroline, Robert, Peter, Hersey, Paul, Nathan, Claus, Garbe, Mohammed, Milhem, Lev V, Demidov, Jessica C, Hassel, Piotr, Rutkowski, Peter, Mohr, Reinhard, Dummer, Uwe, Trefzer, James M G, Larkin, Jochen, Utikal, Brigitte, Dreno, Marta, Nyakas, Mark R, Middleton, Jürgen C, Becker, Michelle, Casey, Laurie J, Sherman, Frank S, Wu, Daniele, Ouellet, Anne-Marie, Martin, Kiran, Patel, Dirk, Schadendorf, Mary, Richardson

المصدر: The New England journal of medicine. 367(2)

مصطلحات موضوعية: Oncology, Adult, Male, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, Dacarbazine, MAP Kinase Kinase 2, Medizin, MAP Kinase Kinase 1, Antineoplastic Agents, Kaplan-Meier Estimate, Pyrimidinones, Disease-Free Survival, chemistry.chemical_compound, Young Adult, Internal medicine, medicine, Humans, Vemurafenib, Melanoma, Protein Kinase Inhibitors, Aged, Trametinib, Cobimetinib, Aged, 80 and over, business.industry, MEK inhibitor, Hazard ratio, Dabrafenib, General Medicine, Middle Aged, medicine.disease, Surgery, Intention to Treat Analysis, chemistry, Mutation, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::778f247f586f7abe700c37ec7f75715aTest
http://ora.ox.ac.uk/objects/uuid:17a4cd0c-72ea-46f7-ab36-457c375b3557Test